You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
國藥中生:「武漢造」新冠滅活疫苗二期擴產項目投產
阿思達克 06-01 08:41
國藥集團中國生物武漢生物製品研究所新冠滅活疫苗二期擴產項目投產活動昨日(5月31日)在武漢舉行。國藥集團董事長劉敬楨在致辭中表示,武漢生物製品研究所新冠滅活疫苗二期擴產項目僅用不到三個月的時間,完成建設並具備投產條件。

該項目僅用86天順利建成並投產,投產後年產能可達10億劑,中國生物新冠疫苗年產能將大幅提升。

據悉,中國生物武漢生物製品研究所與中科院武漢病毒研究所合作研發的新冠病毒滅活疫苗於2021年2月25日獲批附條件上市,新冠滅活疫苗一期車間投入規模化生產,年產能約1億劑次。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account